Kay NE - Search Results

1

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M. Shanafelt TD, et al. Among authors: kay ne. N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073. N Engl J Med. 2019. PMID: 31365801 Free PMC article. Clinical Trial.

2

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. Cheson BD, et al. Blood. 1996 Jun 15;87(12):4990-7. Blood. 1996. PMID: 8652811 Free article. No abstract available.

3

Angiogenesis in B-chronic lymphocytic leukemia.

Kay NE, Jelinek DF, Peterson L. Kay NE, et al. Leuk Res. 2001 Jun;25(6):485-6. doi: 10.1016/s0145-2126(01)00008-x. Leuk Res. 2001. PMID: 11337021 No abstract available.

4

Angiogenesis in B-chronic lymphocytic leukemia.

Kay NE, Jelinek DF, Peterson L. Kay NE, et al. Leuk Res. 2001 Aug;25(8):709-10. doi: 10.1016/s0145-2126(01)00002-9. Leuk Res. 2001. PMID: 11397477 No abstract available.

5

Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.

Jelinek DF, Tschumper RC, Geyer SM, Bone ND, Dewald GW, Hanson CA, Stenson MJ, Witzig TE, Tefferi A, Kay NE. Jelinek DF, et al. Among authors: kay ne. Br J Haematol. 2001 Dec;115(4):854-61. doi: 10.1046/j.1365-2141.2001.03149.x. Br J Haematol. 2001. PMID: 11843819 Free article.

6

B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules.

Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, Hanson CA, Jelinek DF. Kay NE, et al. Leukemia. 2002 May;16(5):911-9. doi: 10.1038/sj.leu.2402467. Leukemia. 2002. PMID: 11986954

7

B-CLL: is the enigma of disease heterogeneity about to be revealed?

Kay NE, Jelinek DF. Kay NE, et al. Blood. 2002 Aug 15;100(4):1110-1. doi: 10.1182/blood.V100.4.1110b. Blood. 2002. PMID: 12149185 Free article. No abstract available.

8

Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival.

Novak AJ, Bram RJ, Kay NE, Jelinek DF. Novak AJ, et al. Among authors: kay ne. Blood. 2002 Oct 15;100(8):2973-9. doi: 10.1182/blood-2002-02-0558. Blood. 2002. PMID: 12351410 Free article.

9

Chronic lymphocytic leukemia.

Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, Lucas M, Lin T. Kay NE, et al. Hematology Am Soc Hematol Educ Program. 2002:193-213. doi: 10.1182/asheducation-2002.1.193. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446424 Review.

10

Identification of a global gene expression signature of B-chronic lymphocytic leukemia.

Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J, Shah N, Kay NE. Jelinek DF, et al. Among authors: kay ne. Mol Cancer Res. 2003 Mar;1(5):346-61. Mol Cancer Res. 2003. PMID: 12651908

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

471 results

Search Page

Filters